Zouves Fertility Center (ZFC), 1241 E Hillsdale Blvd, Foster City, CA, 94404, USA.
J Assist Reprod Genet. 2017 Dec;34(12):1581-1585. doi: 10.1007/s10815-017-1072-6. Epub 2017 Oct 28.
Behind every successful IVF embryo transfer, there is a great game of chance. Methods seeking to tilt the balance and increase the likelihood of implantation have been proposed and implemented with varying results, including embryo morphology, FISH-PGS, comprehensive chromosomal screening (CCS), morphokinetics, endometrial receptivity testing. It has been suggested that mitochondrial DNA (mtDNA) copy number could serve as a biomarker for embryo viability, but this concept was recently challenged. The world of IVF is left with unanswered questions: Why are there discrepancies in the reports? Should mtDNA copy number be considered to rank embryos for transfer? And in a broader sense, how well must a technique be validated before its implementation in the IVF clinic? Here, we explore these questions attempting to piece together the published data and suggest future directions to help unravel the subject matter.
在每一次成功的试管婴儿胚胎移植背后,都存在着一场巨大的机遇游戏。人们提出并实施了各种方法来试图改变平衡,提高着床的可能性,包括胚胎形态学、FISH-PGS、全面染色体筛查(CCS)、形态动力学、子宫内膜容受性检测。有人认为线粒体 DNA(mtDNA)拷贝数可以作为胚胎活力的生物标志物,但这一概念最近受到了挑战。试管婴儿领域仍有许多未解之谜:为什么报告之间存在差异?应该考虑 mtDNA 拷贝数来为胚胎移植进行排名吗?更广泛地说,一项技术在实施到试管婴儿诊所之前需要经过怎样的验证?在这里,我们探讨这些问题,试图整理已发表的数据,并为未来的研究方向提供建议,以帮助解决这个问题。